These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 38129686)
1. Atomistic ensemble of active SHP2 phosphatase. Anselmi M; Hub JS Commun Biol; 2023 Dec; 6(1):1289. PubMed ID: 38129686 [TBL] [Abstract][Full Text] [Related]
2. Discriminating between competing models for the allosteric regulation of oncogenic phosphatase SHP2 by characterizing its active state. Calligari P; Santucci V; Stella L; Bocchinfuso G Comput Struct Biotechnol J; 2021; 19():6125-6139. PubMed ID: 34900129 [TBL] [Abstract][Full Text] [Related]
3. Structural mechanism associated with domain opening in gain-of-function mutations in SHP2 phosphatase. Darian E; Guvench O; Yu B; Qu CK; MacKerell AD Proteins; 2011 May; 79(5):1573-88. PubMed ID: 21365683 [TBL] [Abstract][Full Text] [Related]
5. Experiment-guided molecular simulations define a heterogeneous structural ensemble for the Marasco M; Kirkpatrick J; Carlomagno T; Hub JS; Anselmi M Chem Sci; 2023 May; 14(21):5743-5755. PubMed ID: 37265738 [TBL] [Abstract][Full Text] [Related]
6. Monobody Inhibitor Selective to the Phosphatase Domain of SHP2 and its Use as a Probe for Quantifying SHP2 Allosteric Regulation. Sha F; Kurosawa K; Glasser E; Ketavarapu G; Albazzaz S; Koide A; Koide S J Mol Biol; 2023 Apr; 435(8):168010. PubMed ID: 36806475 [TBL] [Abstract][Full Text] [Related]
7. An allosteric interaction controls the activation mechanism of SHP2 tyrosine phosphatase. Anselmi M; Hub JS Sci Rep; 2020 Oct; 10(1):18530. PubMed ID: 33116231 [TBL] [Abstract][Full Text] [Related]
8. Structure, function, and pathogenesis of SHP2 in developmental disorders and tumorigenesis. Huang WQ; Lin Q; Zhuang X; Cai LL; Ruan RS; Lu ZX; Tzeng CM Curr Cancer Drug Targets; 2014; 14(6):567-88. PubMed ID: 25039348 [TBL] [Abstract][Full Text] [Related]
9. Structural Determinants of Phosphopeptide Binding to the N-Terminal Src Homology 2 Domain of the SHP2 Phosphatase. Anselmi M; Calligari P; Hub JS; Tartaglia M; Bocchinfuso G; Stella L J Chem Inf Model; 2020 Jun; 60(6):3157-3171. PubMed ID: 32395997 [TBL] [Abstract][Full Text] [Related]
10. How a single mutation alters the protein structure: a simulation investigation on protein tyrosine phosphatase SHP2. Hou Y; Lu X; Xu Z; Qu J; Huang J RSC Adv; 2023 Jan; 13(7):4263-4274. PubMed ID: 36760301 [TBL] [Abstract][Full Text] [Related]
11. Structural reorganization of SHP2 by oncogenic mutations and implications for oncoprotein resistance to allosteric inhibition. LaRochelle JR; Fodor M; Vemulapalli V; Mohseni M; Wang P; Stams T; LaMarche MJ; Chopra R; Acker MG; Blacklow SC Nat Commun; 2018 Oct; 9(1):4508. PubMed ID: 30375388 [TBL] [Abstract][Full Text] [Related]
12. The pathogenic T42A mutation in SHP2 rewires the interaction specificity of its N-terminal regulatory domain. van Vlimmeren AE; Voleti R; Chartier CA; Jiang Z; Karandur D; Humphries PA; Lo WL; Shah NH Proc Natl Acad Sci U S A; 2024 Jul; 121(30):e2407159121. PubMed ID: 39012820 [TBL] [Abstract][Full Text] [Related]
13. Gain-of-function mutations in the gene encoding the tyrosine phosphatase SHP2 induce hydrocephalus in a catalytically dependent manner. Zheng H; Yu WM; Waclaw RR; Kontaridis MI; Neel BG; Qu CK Sci Signal; 2018 Mar; 11(522):. PubMed ID: 29559584 [TBL] [Abstract][Full Text] [Related]
14. Mechanistic insights explain the transforming potential of the T507K substitution in the protein-tyrosine phosphatase SHP2. Zhang RY; Yu ZH; Chen L; Walls CD; Zhang S; Wu L; Zhang ZY J Biol Chem; 2020 May; 295(18):6187-6201. PubMed ID: 32188694 [TBL] [Abstract][Full Text] [Related]
15. Structural and Functional Consequences of Three Cancer-Associated Mutations of the Oncogenic Phosphatase SHP2. LaRochelle JR; Fodor M; Xu X; Durzynska I; Fan L; Stams T; Chan HM; LaMarche MJ; Chopra R; Wang P; Fortin PD; Acker MG; Blacklow SC Biochemistry; 2016 Apr; 55(15):2269-77. PubMed ID: 27030275 [TBL] [Abstract][Full Text] [Related]
16. Mechanism of activating mutations and allosteric drug inhibition of the phosphatase SHP2. Pádua RAP; Sun Y; Marko I; Pitsawong W; Stiller JB; Otten R; Kern D Nat Commun; 2018 Oct; 9(1):4507. PubMed ID: 30375376 [TBL] [Abstract][Full Text] [Related]
17. The loops of the N-SH2 binding cleft do not serve as allosteric switch in SHP2 activation. Anselmi M; Hub JS Proc Natl Acad Sci U S A; 2021 Apr; 118(17):. PubMed ID: 33888588 [TBL] [Abstract][Full Text] [Related]
18. Protein tyrosine phosphatase SHP2/PTPN11 mistargeting as a consequence of SH2-domain point mutations associated with Noonan Syndrome and leukemia. Müller PJ; Rigbolt KT; Paterok D; Piehler J; Vanselow J; Lasonder E; Andersen JS; Schaper F; Sobota RM J Proteomics; 2013 Jun; 84():132-47. PubMed ID: 23584145 [TBL] [Abstract][Full Text] [Related]